Physician profile
Gerald M Goltz
NPI 1720033244
$44,372.33
in general payments reported to CMS, 2019-2025
49 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $7,534 · 2021: $7,817 · 2022: $1,846 · 2023: $1,963 · 2024: $2,150 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,123 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,122.83 |
| Education | $104.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31,004.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $3,765.64 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $1,865.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic Minimed, INC. | $1,526.71 | 2019 | |
| Amgen INC. | $658.57 | 2019-2025 | Repatha, Evenity, Tepezza |
| Dexcom, INC. | $603.30 | 2019-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $498.50 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $436.66 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $328.82 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $279.18 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $278.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.26 | 2019-2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $211.20 | 2021-2025 | Unithroid |
| Becton, Dickinson and Company | $210.05 | 2019-2022 | |
| Antares Pharma, INC. | $185.73 | 2021-2025 | Xyosted, Tlando, Nocdurna |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $184.66 | 2021-2025 | Minimed 780g |
| Beta Bionics, INC. | $183.37 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $175.21 | 2025 | Yorvipath |
| Amphastar Pharmaceuticals, INC. | $159.30 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.53 | 2019-2025 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $146.55 | 2019-2023 | |
| Embecta Corp. | $140.54 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ibsa Pharma INC. | $107.69 | 2019-2023 | Tirosint, Licart |
| Madrigal Pharmaceuticals | $92.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Radius Health, INC. | $90.37 | 2022-2025 | Tymlos |
| Abbvie INC. | $83.82 | 2021-2023 | |
| Verity Pharmaceuticals INC. | $76.21 | 2024-2025 | Tlando |
| Neurocrine Biosciences, INC. | $72.00 | 2024-2025 | |
| Corcept Therapeutics | $60.89 | 2022 | |
| Chiesi USA, INC. | $48.98 | 2024 | Mycapssa |
| Mannkind Corporation | $46.94 | 2020-2021 | |
| Astellas Pharma US INC | $44.11 | 2024 | Veozah |
| Pfizer INC. | $42.29 | 2022-2024 | |
| Esperion Therapeutics, INC. | $39.02 | 2025 | Nexletol |
| Halozyme INC | $36.39 | 2023 | |
| Horizon Therapeutics Plc | $34.20 | 2022-2023 | Tepezza |
| Lifescan, INC. | $32.56 | 2022 | |
| Currax Pharmaceuticals LLC | $29.61 | 2023-2025 | Onzetra Xsail, Contrave |
| Janssen Pharmaceuticals, INC | $27.71 | 2019 | |
| Averitas Pharma INC. | $26.59 | 2024 | Qutenza |
| Merck Sharp & Dohme LLC | $26.22 | 2019-2021 | |
| Valeritas, INC. | $23.40 | 2019 | |
| Zealand Pharma US, INC. | $19.35 | 2021 | |
| Cequr Corporation | $19.05 | 2023 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $15.74 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.60 | 2025 | Azmiro |
| Alexion Pharmaceuticals, INC. | $15.29 | 2019 | |
| Sequel Med Tech, LLC | $14.91 | 2025 | Twiist |
| Theracosbio, LLC | $10.93 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Goltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.